Cisplatin (Platinol ®)
Alterations in BAP1 are Associated with Cisplatin Resistance Through Inhibition of Apoptosis in Malignant Pleural Mesothelioma (MPM)
Clinical Cancer Research 2021 February 5 [Link] Kathrin Oehl, Bart Vrugt, Ulrich Wagner, Michaela B Kirschner, Mayura Meerang, Walter Weder, Emanuela Felley-Bosco, Bernd Wollscheid, Katrin Bankov, Melanie C Demes, Isabelle Opitz, Peter J Wild Abstract Purpose: The clinical standard treatment for patients with malignant pleural mesothelioma (MPM) includes a cisplatin-based chemotherapy, leading to reduction of…
Read MoreFirst-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Lancet 2021 January 21 [Link] Paul Baas, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz Kowalski, Jerónimo Rodríguez-Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman Abstract Background: Approved systemic treatments…
Read MoreEstablishment and Characterization of Patient-Derived Xenografts (PDXs) of Different Histology from Malignant Pleural Mesothelioma Patients
Cancers 2020 December 20 [Link] Roberta Affatato, Paolo Mendogni, Alessandro Del Gobbo, Stefano Ferrero, Francesca Ricci, Massimo Broggini, Lorenzo Rosso Abstract Background: Malignant pleural mesothelioma (MPM) is a very aggressive tumor originating from mesothelial cells. Although several etiological factors were reported to contribute to MPM onset, environmental exposure to asbestos is certainly a major risk…
Read MoreThe Impact on Outcome by Adding Bevacizumab to Standard Induction Chemotherapy Prior to Mesothelioma Surgery: A Retrospective Single Center Analysis
Frontiers in Oncology 2020 November 13 [Link] Olivia Lauk, Karina Bruestle, Thomas Neuer, Bianca Battilana, Thi Dan Linh Nguyen, Thomas Frauenfelder, Rolf Stahel, Walter Weder, Alessandra Curioni-Fontecedro, Isabelle Opitz Abstract Objectives: Adding bevacizumab, an anti-Vascular Endothelial Growth Factor (VEGF), to platinum-based chemotherapy/pemetrexed in 1st line treatment of advanced malignant pleural mesothelioma (MPM), significantly improved overall…
Read MoreOncolytic herpesvirus therapy for mesothelioma – A phase I/IIa trial of intrapleural administration of HSV1716
Lung Cancer 2020 October 20 [Link] Sarah J Danson, Joe Conner, John G Edwards, Kevin G Blyth, Patricia M Fisher, Munitta Muthana, Abdulazeez Salawu, Fiona Taylor, Elizabeth Hodgkinson, Patrick Joyce, Jennifer Roman, Kathleen Simpson, Alexander Graham, Kirsty Learmonth, Penella J Woll Abstract Objectives: Malignant Pleural Mesothelioma (MPM) remains a major oncological challenge with limited therapeutic…
Read MoreImpact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
Scientific Reports 2020 October 29 [Link] Sabrina Borchert, Pia-Maria Suckrau, Robert F H Walter, Michael Wessolly, Elena Mairinger, Julia Steinborn, Balazs Hegedus, Thomas Hager, Thomas Herold, Wilfried E E Eberhardt, Jeremias Wohlschlaeger, Clemens Aigner, Agnes Bankfalvi, Kurt Werner Schmid, Fabian D Mairinger Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with dismal…
Read MoreLocoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma
Thoracic Cancer 2020 October 8 [Link] Oscar Arrieta, Francisco Lozano-Ruiz, Monika Blake-Cerda, Rodrigo Catalán, Luis Lara-Mejía, Miguel Ángel Salinas, Federico Maldonado-Magos, José F Corona-Cruz Abstract Background: Treatment of malignant pleural mesothelioma (MPM) represents a major challenge for oncologists. Multimodality treatment, which generally involves induction chemotherapy, surgery and radiotherapy have recently shown promising results. The aim…
Read MoreImmunotherapy for mesothelioma: rationale and new approaches
Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past decade. Recently, however, immune checkpoint blockade (ICB) targeting the programmed death 1 and cytotoxic T-lymphocyte-associated antigen 4 pathways has revolutionized the treatment of multiple malignancies…
Read MoreA multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
Annals of Oncology 2020 September 22 [Link] S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O’Brien, A Pope, P Fisher, J Spicer, A Roy, D Gilligan, O Gautschi, E Nadal, W D Janthur, R López Castro, R García Campelo, S Rusakiewicz, I Letovanec, V Polydoropoulou, H Roschitzki-Voser, B Ruepp, A Gasca-Ruchti, S Peters, R…
Read MoreDurvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in
The Lancet Oncology 2020 September [Link] Anna K Nowak, W Joost Lesterhuis, Peey-Sei Kok, Chris Brown, Brett Gm Hughes, Deme J Karikios, Thomas John, Steven C-H Kao, Connull Leslie, Alistair M Cook, Nick Pavlakis, Karen Briscoe, Kenneth J O’Byrne, Christos S Karapetis, Wei-Sen Lam, Ailsa Langford, Sonia Yip, Martin R Stockler Abstract Background: There is…
Read More